AI Summary
In the phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial, Niraparib first-line maintenance therapy showed significant improvement in progression-free survival (PFS) for patients with newly diagnosed advanced ovarian cancer (aOC) who responded to first-line platinum-based chemotherapy, regardless of homologous recombination deficiency (HRD) status. The final overall survival (OS) results are reported, indicating the potential benefits of this treatment approach.
The phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial met its primary endpoint. Niraparib first-line maintenance significantly prolonged progression-free survival (PFS) among patients with newly diagnosed advanced ovarian cancer (aOC) that responded to first-line platinum-based chemotherapy, regardless of homologous recombination deficiency (HRD) status. Final overall survival (OS) results are reported.